Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated
Samsung Biologics speeds $2B plant build forecast to boost capacity 70%
Q3 2021's health tech funding blows previous years out of the water
Caris Life Sciences, freshly past $1B VC funding mark, finds new finance head in ex-Medtronic SVP
Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst
Takeda's transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study
ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making
DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light
Schrödinger ropes MD Anderson into its development program for cancer inhibitors
FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editing
Optum, SSM Health team up to tackle healthcare affordability, accessibility
UCHealth stands firm on denying organ transplants to patients, donors who are unvaccinated for COVID-19

Featured Story

Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated

By Ben Adams

As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO.

Samsung Biologics speeds $2B plant build forecast to boost capacity 70%

By Joseph Keenan

Samsung Biologics is pushing for early completion of its new $2 billion manufacturing facility in an effort to meet increased demand and boost the South Korean CMO giant’s profits.

Q3 2021's health tech funding blows previous years out of the water

By Dave Muoio

Third quarter reports from Rock Health and StartUp Health place digital health funding at $6.7 billion and health innovation funding at $9.7 billion, respectively. Both groups also highlighted increases in fundraising deal size as well as merger and acquisition volume.

Caris Life Sciences, freshly past $1B VC funding mark, finds new finance head in ex-Medtronic SVP

By Andrea Park

With great power comes great responsibility, and that’s surely the case for Caris Life Sciences’ new chief financial officer, who takes on the role as the sequencing startup enters an entirely new financial realm.

Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst

By Angus Liu

With Lumakras the first drug specifically approved for KRAS-mutated cancer, Amgen is examining various combination options to expand its reach. But new data underline the difficulty in finding the right partner.

Takeda's transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study

By Nick Paul Taylor

Takeda’s faltering effort to deliver a wave of new products that will drive sales growth over the next decade has received a boost. Having seen its other prospects stumble in recent months, Takeda got back on track with unanimous FDA advisory committee votes in favor of a transplant drug.

ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making

By Kevin Dunleavy

ChemoCentryx has scored an FDA approval for Tavneos, an oral treatment for vasculitis, which leads to inflammation and destruction of small blood vessels. It is the first approval for ChemoCentryx in its 24-year history. The drug becomes the first approved in more than a decade for ANCA vasculitis.

DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light

By Conor Hale

It’s a common difficulty in many medical specialties: there typically aren’t enough specialists to go around. DreaMed Diabetes hopes to relieve some of the strain with its artificial-intelligence-powered system aimed not at patients but at clinicians.

PM Tracker

Featured Story

Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated

Top Stories

Samsung Biologics speeds $2B plant build forecast to boost capacity 70%

Q3 2021's health tech funding blows previous years out of the water

Caris Life Sciences, freshly past $1B VC funding mark, finds new finance head in ex-Medtronic SVP

Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst

Takeda's transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study

ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making

DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light

Schrödinger ropes MD Anderson into its development program for cancer inhibitors

FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editing

Optum, SSM Health team up to tackle healthcare affordability, accessibility

UCHealth stands firm on denying organ transplants to patients, donors who are unvaccinated for COVID-19